Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 10/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468122 | 0.92 | MET (0.81) | METHDAC1 | |
| SCHEMBL2469567 | 0.90 | MET (0.67) | METMEN1KMT2AHDAC1ALDH1A1 | |
| SCHEMBL2493573 | 0.90 | MET (0.61) | METMEN1KMT2AALDH1A1MKNK1 | |
| SCHEMBL2672558 | 0.88 | MET (0.64) | METMEN1KMT2AHDAC1ALDH1A1 | |
| SCHEMBL4126839 | 0.87 | MET (0.86) | METMEN1KMT2A | |
| SCHEMBL2466162 | 0.85 | MET (0.60) | METALDH1A1 | |
| SCHEMBL4124593 | 0.84 | PDE4A (0.69) | MET | |
| SCHEMBL2465886 | 0.83 | MET (0.55) | METMEN1KMT2AHDAC1ALDH1A1 | |
| SCHEMBL2464489 | 0.82 | MET (0.79) | METHDAC1 | |
| SCHEMBL15815401 | 0.82 | CHEK1 (0.70) | METMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| EP-1960370-B1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007065518-A1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MET, RET, ERBB2 | MET 1/4885MEN1 167/4885KMT2A 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.